Biotechnology News

Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters.

CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND...

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced...

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.

SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...

REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph®...

Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the...

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate  Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN,...

The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring...